P149 Evaluating outcomes for patients with systemic lupus erythematosus treated with obinutuzumab, a humanised anti-CD20 monoclonal antibody, following secondary non-depletion of B cells and non-response with rituximab
Vikram M K Joseph(University College Hospital), Maria Leandro(University College Hospital), Corinne Fisher(University College Hospital), Venkat Reddy(University College London), Michael R. Ehrenstein, Coziana Ciurtin(University College Hospital), Ruth J. Pepper(University College Hospital)
Cited by 1
Related Papers
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids
|Annals of the Rheumatic Diseases|2013|454
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease
|Lara D. Veeken|2003|367
Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion
|Annals of the Rheumatic Diseases|2002|342
Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids
|Nephrology Dialysis Transplantation|2009|156